Baicalin administration is effective in positive regulation of twenty-four ischemia/reperfusion-related proteins identified by a proteomic study.
ABSTRACT Baicalin is a major plant polyphenolic compound derived from the dried root of Scutellaria baicalensis Georgi, a Traditional Chinese Medicine material. The current study applied proteomics to investigate the different protein expression modes in mice brains after middle cerebral artery occlusion (MCAO) with or without administration of baicalin. Twenty-four proteins which had a 3-fold change in abundance compared to the sham control sample were selected to be identified. Statistical analysis demonstrated that there was no significant difference in expression between the twenty-four proteins baicalin-treated MCAO group and the sham-operation group (n=24, p=0.102). Gene Ontology analysis linked these proteins to fifteen biological processes, including cellular process, developmental process and biological regulation. Results indicated that baicalin performed well in regulating proteins in energy metabolism but had a relatively weak effect in the regulation of proteins in neurogenesis and apoptosis. In sum, our findings suggest baicalin may be a potential therapeutic agent in treating stroke and may also be a strong candidate for future research in its actions on individual proteins.
Article: Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia/reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers.[show abstract] [hide abstract]
ABSTRACT: Cerebral ischemia or stroke, an acute neurological injury lacking an effective therapy, is the second leading cause of death globally. The unmet need in stroke research is to identify viable targets and to understand their interplay during the temporal evolution of ischemia/reperfusion (I/R) injury. Here we report a temporal signature of the ischemic hemisphere revealed by the isobaric tag for relative and absolute quantification (iTRAQ)-based 2D-LC-MS/MS strategy in an in vivo middle cerebral artery occlusion (MCAO) model of focal cerebral I/R injury. To recapitulate clinical stroke, two hours of MCAO was followed by 0, 4, and 24 h of reperfusion to capture ischemia with an acute and subacute durations of reperfusion injury. The subsequent iTRAQ experiment identified 2242 proteins from the ischemic hemisphere with <1.0% false discovery rate. Data mining revealed that (1) about 2.7% of detected proteins were temporally perturbed having an involvement in the energy metabolism (Pygb, Atp5b), glutamate excitotoxicity (Slc1a3, Glud1), neuro-inflammation (Tf, C3, Alb), and cerebral plasticity (Gfap, Vim, Gap43); (2) astrocytes participated actively in the neurometabolic coupling underlining the importance of a cerebro-protective rather than a neuro-protective approach; and (3) hyper-acute yet progressive opening of the blood brain barrier (BBB), accompanied by stimulation of an innate immune response and late activation of a regenerative response, which provides an extended therapeutic window for intervention. Several regulated proteins (Caskin1, Shank3, Kpnb1, Uchl1, Mtap6, Epb4.1l1, Apba1, and Ube1x) novel in the context of stroke were also discovered. In conclusion, our result supports a dynamic multitarget therapy rather than the traditional approach of a unilateral and sustained modulation of a single target to address the phasic regulation of an ischemic proteome.Journal of Proteome Research 09/2011; 10(11):5199-213. · 5.11 Impact Factor